KCT0000540已完成未知
Phase I study to Determine the Safety and Immunogenicity of Euvichol(Oral Cholera Prevention Vaccine)in Healthy Adult Men ; Open, Non-comparative clinical trial
Eubiologics0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit(—)
- 性别
- Male
入选标准
- •1) Adult men over 20years of age
- •2) More than 45kg body weight and ideal body weight within ±20% of the weight
- •3)Screening was conducted within 14 days of investigational drug administration (Vital Sign & Physical Examination, hematology and blood coagulation tests, blood chemistry tests, urinalysis, 12-lead ECG, etc.), the results at the discretion of the investigator deemed suitable for participation in clinical trials
- •4) Written consent person who determines to participate in a clinical trial
排除标准
- •1) A person who showed hypersensitivity when other preventive vaccination in the past
- •2) A person who have received cholera vaccine in the past
- •3) A person who had a febrile illness or infection disease, or have received antibiotics within 2weeks before the start of the experiment
- •4) A person who had gastrointestinal symptoms such as diarrhea, abdominal pain, or have been received prescription drug within one week before the start of the experiment
- •5) A person who was lasted for more than two weeks of symptoms such as diarrhea, abdominal pain within 6months before the start of the experiment
- •6) A person who donate whole blood or component of blood within one months before the start of the experiment if the donors
- •7) A person who received other preventive vaccine within 2months before the start of the experiment
- •8) A person who received blood products of immune globulin preparatios within 3months before the start of the experiment
- •9) A person who has immune function disorders or are receiving immunosuppressive treatment
- •10) A person who has chronic illness in progress
- •11) Ongoing drug and alcohol abuse(Not more than 28 units/week for drinking)
- •12) A person who participate in clinical trials treated with the investigational drug within 2months before the start of the experiment
- •13) A person who is difficult to participate in this clinical trials as the discretion of the investigator
研究者
相似试验
进行中(未招募)
1 期
A study of a new vaccine against the MERS virus in adults aged 50 to 70 yearsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) infectionInfections and InfestationsISRCTN17936606niversity of Oxford84
已完成
1 期
Safety and immunogenicity of a new tuberculosis (TB) vaccine (MVA85A) in healthy volunteers in Cape TowTuberculosisISRCTN17498868niversity of Oxford (UK)36
未知
1 期
DNK-651-1JPRN-jRCT2080223171DENKA SEIKEN CO.,LTD.
尚未招募
不适用
Malaria vectored vaccines and EPI co-administration trial (VAC 058)MalariaPACTR201402000749217THE JENNER INSTITUTE, UNIVERSITY OF OXFORD65
招募中
1 期
Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)2024-518355-36-01Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)24
